Valuation: Ipsen

Market Cap 1.22TCr 1.36TCr 1.13TCr 1.03TCr 1.94TCr 1,29200Cr 1.97TCr 14TCr 5.32TCr 67TCr 5.12TCr 5.01TCr 2,15700Cr P/E 2026 *
12.4x
P/E 2027 * 12.3x
Enterprise Value 1.09TCr 1.22TCr 1.01TCr 923.06Cr 1.74TCr 1,15900Cr 1.77TCr 12TCr 4.77TCr 60TCr 4.59TCr 4.49TCr 1,93400Cr EV / Sales 2026 *
2.38x
EV / Sales 2027 * 2.13x
Free-Float
40.65%
Yield 2026 *
1.03%
Yield 2027 * 1.05%
1 day+0.61%
1 week+4.70%
Current month+5.14%
1 month-5.80%
3 months-5.38%
6 months-8.12%
Current year+25.55%
1 week 141.6
Extreme 141.6
151.1
1 month 138.3
Extreme 138.3
159.6
Current year 116
Extreme 116
174
1 year 112.7
Extreme 112.7
174
3 years 87.95
Extreme 87.95
174
5 years 77
Extreme 77
174
10 years 34.2
Extreme 34.2
174
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/26 Buy

Director

500 0.0006%
08/09/26 Buy

Director

500 0.0006%
03/09/26 Sell

Director

-1,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%+4.70%+30.59%+26.61% 1.36TCr
+1.44%+7.48%+54.69%+105.55% 1,11600Cr
+1.53%-2.06%+33.28%+62.55% 61TCr
+0.86%+2.88%+25.37%+93.18% 50TCr
+1.14%+0.46%+74.30%+40.46% 36TCr
-0.49%+5.53%+32.35%+49.75% 37TCr
-0.94%+4.47%+19.24%+42.68% 29TCr
-1.80%+3.67%-0.92%+13.36% 26TCr
+0.93%+5.07%+47.36%+51.95% 23TCr
-0.42%+3.37%+32.60%+97.31% 20TCr
Average +0.30%+4.99%+34.89%+58.34% 39.43TCr
Weighted average by Cap. +0.68%+4.75%+39.48%+71.67%

Financials

2026 *2027 *
Net sales 458.57Cr 513.75Cr 426.2Cr 387.68Cr 729.37Cr 49TCr 742.52Cr 5.12TCr 2TCr 25TCr 1.93TCr 1.89TCr 81TCr 471.37Cr 528.09Cr 438.09Cr 398.5Cr 749.73Cr 50TCr 763.24Cr 5.26TCr 2.06TCr 26TCr 1.98TCr 1.94TCr 84TCr
Net income 100.84Cr 112.97Cr 94Cr 85Cr 160.39Cr 11TCr 163.28Cr 1.13TCr 440.49Cr 5.58TCr 423.96Cr 414.98Cr 18TCr 102.36Cr 114.68Cr 95Cr 87Cr 162.81Cr 11TCr 165.75Cr 1.14TCr 447.14Cr 5.67TCr 430.36Cr 421.24Cr 18TCr
Net Debt -125.7Cr -140.82Cr -116.82Cr -106.26Cr -199.92Cr -13TCr -203.53Cr -1.4TCr -549.05Cr -6.96TCr -528.45Cr -517.26Cr -22TCr -214.74Cr -240.57Cr -199.58Cr -181.54Cr -341.55Cr -23TCr -347.7Cr -2.4TCr -938Cr -12TCr -902.8Cr -883.68Cr -38TCr
Projected Income Statement - Annual - Ipsen
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
16/26/16 €148.90 +0.27% 54,009
15/26/15 €148.50 +1.99% 1,45,250
14/26/14 €145.60 +2.10% 1,63,923
13/26/13 €142.60 -1.04% 99,154
12/26/12 €144.10 +0.98% 76,047
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Ipsen
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
148.50EUR
Average target price
164.29EUR
Spread / Average Target
+10.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipsen